Brenig Therapeutics Unveils Superior Safety Profile of LRRK2 Inhibitor BT-0267 with Exceptional CSF/Plasma Ratio at Future of Parkinson’s Disease Conference

Posted on by

SAN DIEGO, Dec. 4, 2023 /PRNewswire/ — Brenig Therapeutics, a portfolio company of Torrey Pines Investments, OrbiMed Advisors, and BioGeneration Ventures, announces new data on its LRRK2 inhibitor drug candidate, BT-0267. The results were unveiled at the prestigious Future of Parkinson’s…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.